Biggest changeFixed Maturities, Available for Sale The following table summarizes the carrying values and gross unrealized losses of our fixed maturity securities, available for sale, by category as of December 31, 2023 (dollars in millions): Carrying value Percent of fixed maturities Gross unrealized losses Percent of gross unrealized losses States and political subdivisions $ 2,566.7 11.9 % $ 360.7 15.6 % Commercial mortgage-backed securities 2,218.1 10.3 270.0 11.7 Banks 1,815.6 8.5 193.9 8.3 Non-agency residential mortgage-backed securities 1,553.2 7.2 152.7 6.6 Asset-backed securities 1,372.4 6.4 107.8 4.7 Insurance 1,125.0 5.2 165.7 7.2 Utilities 1,114.3 5.2 139.3 6.0 Healthcare/pharmaceuticals 1,045.6 4.9 167.7 7.3 Collateralized loan obligations 1,032.8 4.8 13.0 .6 Brokerage 947.2 4.4 103.6 4.5 Technology 779.0 3.6 111.6 4.8 Food/beverage 667.4 3.1 61.3 2.7 Agency residential mortgage-backed securities 648.0 3.0 .5 — Energy 502.6 2.3 30.7 1.3 Cable/media 470.4 2.2 61.1 2.6 Real estate/REITs 337.8 1.6 42.3 1.8 Transportation 332.2 1.6 30.5 1.3 Telecom 331.5 1.5 17.6 .8 Capital goods 280.1 1.3 25.8 1.1 Chemicals 259.5 1.2 29.2 1.3 Education 243.9 1.1 48.2 2.1 Other 1,862.9 8.7 177.6 7.7 Total fixed maturities, available for sale $ 21,506.2 100.0 % $ 2,310.8 100.0 % 72 Table of Contents The following table summarizes the gross unrealized losses of our fixed maturity securities, available for sale, by category and ratings category as of December 31, 2023 (dollars in millions): Investment grade Below-investment grade AAA/AA/A BBB BB B+ and below Total gross unrealized losses States and political subdivisions $ 352.7 $ 7.5 $ — $ .5 $ 360.7 Commercial mortgage-backed securities 196.9 44.0 21.1 8.0 270.0 Banks 100.1 88.8 5.0 — 193.9 Healthcare/pharmaceuticals 126.3 39.1 1.7 .6 167.7 Insurance 84.2 78.9 2.5 .1 165.7 Non-agency residential mortgage-backed securities 92.8 43.5 .9 15.5 152.7 Utilities 81.9 56.3 1.1 — 139.3 Technology 74.2 34.7 2.4 .3 111.6 Asset-backed securities 39.3 53.1 15.0 .4 107.8 Brokerage 51.1 51.5 .7 .3 103.6 Food/beverage 21.1 39.0 1.0 .2 61.3 Cable/media 7.1 49.7 2.2 2.1 61.1 Real estate/REITs 26.1 16.0 .2 — 42.3 Consumer products 20.5 9.5 2.1 .6 32.7 Energy 5.3 25.2 .1 — 30.6 Transportation 12.6 17.8 — .1 30.5 Chemicals 2.2 26.4 .3 .2 29.1 Retail 17.0 4.3 6.0 .8 28.1 Capital goods 14.3 10.1 1.5 — 25.9 Autos 3.4 14.5 .2 .2 18.3 Aerospace/defense 4.8 13.1 — .2 18.1 Telecom — 17.5 .1 — 17.6 Building materials 4.5 12.0 .3 .2 17.0 United States Treasury securities and obligations of United States government corporations and agencies 13.3 — — — 13.3 Collateralized loan obligations 11.7 1.3 — — 13.0 Metals and mining 3.7 7.4 .4 — 11.5 Foreign governments 5.0 5.4 — — 10.4 Entertainment/hotels 5.0 3.5 — — 8.5 Paper .6 7.2 — .2 8.0 Other 55.1 4.7 .4 .3 60.5 Total fixed maturities, available for sale $ 1,432.8 $ 782.0 $ 65.2 $ 30.8 $ 2,310.8 73 Table of Contents Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations (Moody's, S&P or Fitch), or if not rated by such firms, the rating assigned by the NAIC.
Biggest changeIn light of these statutes and regulations and our capital management strategy, we generally seek to invest in (i) highly rated securities such as United States government and government-agency securities and corporate securities rated investment grade by established nationally recognized rating organizations; (ii) securities of comparable investment quality, if not rated; or (iii) a limited quantity of other investments which offer differentiated return characteristics. 76 Table of Co n t e n t s Fixed Maturities, Available for Sale The following table summarizes the carrying values and gross unrealized losses of our fixed maturity securities, available for sale, by category as of December 31, 2024 (dollars in millions): Carrying value Percent of fixed maturities Gross unrealized losses Percent of gross unrealized losses States and political subdivisions $ 2,834.3 12.4 % $ 436.4 17.2 % Commercial mortgage-backed securities 2,197.5 9.6 183.7 7.2 Banks 1,832.1 8.0 191.2 7.6 Non-agency residential mortgage-backed securities 1,539.1 6.7 130.8 5.2 Asset-backed securities 1,516.4 6.6 66.5 2.6 Insurance 1,155.1 5.1 186.9 7.4 Utilities 1,152.1 5.0 160.9 6.3 Brokerage 1,041.7 4.6 102.3 4.0 Healthcare/pharmaceuticals 1,030.3 4.5 227.8 9.0 Collateralized loan obligations 1,016.8 4.5 4.0 0.2 Agency residential mortgage-backed securities 819.6 3.6 5.5 0.2 Technology 706.3 3.1 146.4 5.8 Food/beverage 581.2 2.6 90.4 3.6 Certificates of deposit 488.3 2.1 — — Energy 475.9 2.1 42.9 1.7 Cable/media 466.8 2.0 75.6 3.0 Transportation 344.3 1.5 42.7 1.7 Real estate/REITs 328.7 1.4 41.5 1.6 Telecom 302.7 1.3 33.6 1.3 Capital goods 289.9 1.3 33.5 1.3 Chemicals 277.9 1.2 35.3 1.4 Autos 239.6 1.1 23.3 0.9 Other 2,203.9 9.7 272.9 10.8 Total fixed maturities, available for sale $ 22,840.5 100.0 % $ 2,534.1 100.0 % 77 Table of Co n t e n t s The following table summarizes the gross unrealized losses of our fixed maturity securities, available for sale, by category and ratings category as of December 31, 2024 (dollars in millions): Investment grade Below-investment grade AAA/AA/A BBB BB B+ and below Total gross unrealized losses States and political subdivisions $ 426.9 $ 7.7 $ — $ 1.8 $ 436.4 Healthcare/pharmaceuticals 163.2 62.6 2.0 — 227.8 Banks 120.6 68.3 2.3 — 191.2 Insurance 102.5 81.4 3.0 — 186.9 Commercial mortgage-backed securities 136.0 21.8 14.8 11.1 183.7 Utilities 104.3 55.8 0.8 — 160.9 Technology 86.6 57.5 2.2 0.1 146.4 Non-agency residential mortgage-backed securities 95.6 26.0 0.6 8.6 130.8 Brokerage 62.9 38.5 0.6 0.3 102.3 Food/beverage 31.6 57.9 0.8 0.1 90.4 Cable/media 13.1 60.1 1.3 1.1 75.6 Asset-backed securities 25.1 31.5 9.8 0.1 66.5 Education 52.9 5.2 — — 58.1 Energy 9.8 33.1 — — 42.9 Transportation 20.1 22.6 — — 42.7 Real estate/REITs 27.1 14.3 0.1 — 41.5 Consumer products 22.9 12.5 2.9 0.5 38.8 Chemicals 2.9 32.0 0.3 0.1 35.3 Retail 23.4 2.7 1.0 6.8 33.9 Telecom 0.3 33.3 — — 33.6 Capital goods 19.3 12.6 1.6 — 33.5 United States Treasury securities and obligations of United States government corporations and agencies 28.6 — — — 28.6 Aerospace/defense 7.0 18.0 — 0.1 25.1 Autos 5.2 17.8 0.2 0.1 23.3 Building materials 5.7 15.5 0.3 0.1 21.6 Metals and mining 6.5 9.2 0.5 — 16.2 Foreign governments 6.7 8.6 — — 15.3 Paper 0.4 11.4 — 0.1 11.9 Entertainment/hotels 6.6 3.7 0.1 — 10.4 Agency residential mortgage-backed securities 5.5 — — — 5.5 Collateralized loan obligations 4.0 — — — 4.0 Business services — 1.3 0.3 0.5 2.1 Other 9.7 1.0 0.1 0.1 10.9 Total fixed maturities, available for sale $ 1,633.0 $ 823.9 $ 45.6 $ 31.6 $ 2,534.1 78 Table of Co n t e n t s Investment ratings are assigned the second lowest rating by Nationally Recognized Statistical Rating Organizations (Moody's, S&P or Fitch), or if not rated by such firms, the rating assigned by the NAIC.
Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes.
Income from insurance products is the sum of the insurance margins of the annuity, health and life product lines, less expenses allocated to the insurance lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes.
We estimated these payments based on our historical experience and our expectation of future payment patterns which is consistent with the assumptions used in our reserve calculations for these blocks of business. • The average interest rate we assumed would be credited to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or fixed indexed products) over the term of the contracts was 4.4 percent.
We estimated these payments based on our historical experience and our expectation of future payment patterns which is consistent with the assumptions used in our reserve calculations for these blocks of business. • The average interest rate we assumed would be credited to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or fixed indexed products) over the term of the contracts was 4.3 percent.
Such 4.4 percent rate includes interest credited to annuity and universal life products as well as the rates assumed in our calculations of reserves for health and traditional life products which are set based on investment yields at policy issuance and are locked-in in accordance with current accounting requirements. Refer to "Part 1 - Item 1A.
Such 4.3 percent rate includes interest credited to annuity and universal life products as well as the rates assumed in our calculations of reserves for health and traditional life products which are set based on investment yields at policy issuance and are locked-in in accordance with current accounting requirements. Refer to "Part 1 - Item 1A.
At December 31, 2023, the carrying value of the FHLB common stock was $94.6 million. As of December 31, 2023, collateralized borrowings from the FHLB totaled $2.2 billion and the proceeds were used to purchase matched variable rate fixed maturity securities. The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.
At December 31, 2024, the carrying value of the FHLB common stock was $94.6 million. As of December 31, 2024, collateralized borrowings from the FHLB totaled $2.2 billion and the proceeds were used to purchase matched variable rate fixed maturity securities. The borrowings are classified as investment borrowings in the accompanying consolidated balance sheet.
Our RBC ratio at December 31, 2023, exceeded our targeted statutory RBC ratio of 375 percent and the minimum 350 percent that is reflected in our risk appetite statement that we share and discuss with rating agencies and insurance regulators. We believe that the 375 percent RBC ratio target continues to adequately support our financial strength and credit ratings.
Our RBC ratio at December 31, 2024, exceeded our targeted statutory RBC ratio of 375 percent and the minimum 350 percent that is reflected in our risk appetite statement that we share and discuss with rating agencies and insurance regulators. We believe that the 375 percent RBC ratio target continues to adequately support our financial strength and credit ratings.
(b) Includes projected interest payments based on interest rates, as applicable, as of December 31, 2023. Refer to the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for additional information on notes payable. (c) These borrowings represent collateralized borrowings from the FHLB and projected interest payments on such borrowings.
(b) Includes projected interest payments based on interest rates, as applicable, as of December 31, 2024. Refer to the note to the consolidated financial statements entitled "Notes Payable - Direct Corporate Obligations" for additional information on notes payable. (c) These borrowings represent collateralized borrowings from the FHLB and projected interest payments on such borrowings.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF CONSOLIDATED FINANCIAL CONDITION AND RESULTS OF OPERATIONS. In this section, we review the consolidated financial condition of CNO and its consolidated results of operations for the years ended December 31, 2023, 2022 and 2021 and, where appropriate, factors that may affect future financial performance.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF CONSOLIDATED FINANCIAL CONDITION AND RESULTS OF OPERATIONS. In this section, we review the consolidated financial condition of CNO and its consolidated results of operations for the years ended December 31, 2024, 2023 and 2022 and, where appropriate, factors that may affect future financial performance.
When recognizing an allowance associated with a credit loss, the cost basis is not adjusted. When we determine a security is uncollectable, the remaining amortized cost will be written off. In determining the credit loss component, we discount the estimated cash flows on a security by security basis.
When recognizing an allowance associated with a credit loss, the cost basis is not adjusted. When we determine a security is uncollectible, the remaining amortized cost will be written off. In determining the credit loss component, we discount the estimated cash flows on a security by security basis.
We consider the impact of macroeconomic conditions on inputs used to measure the amount of credit loss. For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including overcollateralization, excess spread, subordination and guarantees.
We consider the impact of macroeconomic conditions on inputs used to measure the amount of credit loss. For most structured securities, cash flow estimates are based on bond-specific facts and circumstances that may include collateral characteristics, expectations of delinquency and default rates, loss severity, prepayment speeds and structural support, including over-collateralization, excess spread, subordination and guarantees.
Our estimates of future taxable income are based on evidence we consider to be objectively verifiable. At December 31, 2023, our projection of future taxable income for purposes of determining the valuation allowance is based on our estimates of such future taxable income through the date our NOLs expire.
Our estimates of future taxable income are based on evidence we consider to be objectively verifiable. At December 31, 2024, our projection of future taxable income for purposes of determining the valuation allowance is based on our estimates of such future taxable income through the date our NOLs expire.
Future regulatory changes made by the BMA may impact the capital efficiency of the reinsurance structure and could require the holding company to contribute additional capital to CNO Bermuda Re or Bankers Life to recapture the ceded business.
Future regulatory changes made by the BMA or other events may impact the capital efficiency of the reinsurance structure and could require the holding company to contribute additional capital to CNO Bermuda Re or Bankers Life to recapture the ceded business.
During 2023, the financial statements of three of our U.S. based insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities reflected asset adequacy or premium deficiency reserves.
During 2024, the financial statements of three of our U.S. based insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities reflected asset adequacy or premium deficiency reserves.
Many of our products include surrender charges, market interest rate adjustments or other features to encourage persistency; however, at December 31, 2023, approximately $4.4 billion of our total insurance liabilities could be surrendered by the policyholder without penalty. Finally, changes in interest rates can have significant effects on our investment portfolio.
Many of our products include surrender charges, market interest rate adjustments or other features to encourage persistency; however, at December 31, 2024, approximately $3.4 billion of our total insurance liabilities could be surrendered by the policyholder without penalty. Finally, changes in interest rates can have significant effects on our investment portfolio.
Management believes this information helps provide a better understanding of the business and a more meaningful analysis of the results of our insurance product lines. Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average insurance liabilities for the block in each period.
Management believes this information helps provide an additional understanding of the business and a more meaningful analysis of the results of our insurance product lines. Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average insurance liabilities for the block in each period.
In addition, we also review and update our assumptions on a more frequent basis to the extent current conditions or circumstances warrant changes that could be significant to our operating results. The impacts of these unlocking exercises have had a significant impact on our earnings.
In addition, we also review and update our assumptions on a more frequent basis to the extent current conditions or circumstances warrant changes that could be significant to our operating results. The impacts of the review have had a significant impact on our earnings.
Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense 49 Table of Contents on notes payable and investment borrowings; (iv) expenses related to the funding agreement-backed note ("FABN") program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders.
Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the funding agreement-backed note ("FABN") program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders.
Management believes insurance product margin and income from insurance products help provide a better understanding of the business and a more meaningful analysis of the results of our insurance product lines. We market our products through the Consumer and Worksite Divisions that reflect the customers served by the Company.
Management believes insurance product margin and income from insurance products help provide an additional understanding of the business and a more meaningful analysis of the results of our insurance product lines. We market our products through the Consumer and Worksite Divisions that reflect the customers served by the Company.
If we intend to sell an impaired fixed maturity security, available for sale, or identify an impaired fixed maturity security, available for sale, for which is it more likely than not we will be required to sell before anticipated recovery, the 52 Table of Contents difference between the fair value and the amortized cost is included in net investment gains (losses) and the fair value becomes the new amortized cost.
If we intend to sell an impaired fixed maturity security, available for sale, or identify an impaired fixed maturity security, available for sale, for which is it more likely than not we will be required to sell before anticipated recovery, the difference between the fair value and the amortized cost is included in net investment gains (losses) and the fair value becomes the new amortized cost.
The most significant impacts related to supplemental health and Medicare supplement products which were favorably (unfavorably) impacted by $41.9 million and $(10.6) million, respectively. The primary supplemental health changes related to lower morbidity and higher surrender assumptions. The primary Medicare supplement changes related to higher near-term morbidity and higher persistency assumptions.
The most significant impacts related to supplemental health and Medicare supplement products which were favorably (unfavorably) impacted by $41.9 million and $(10.6) million, respectively. The primary supplemental health changes related to lower morbidity and higher surrender assumptions.
We cannot be assured that the regulators will not seek to assert greater supervision and control over our insurance subsidiaries' businesses and financial affairs. Our estimated consolidated statutory RBC ratio of our U.S. based insurance subsidiaries was 402 percent at December 31, 2023, compared to 384 percent at December 31, 2022.
We cannot be assured that the regulators will not seek to assert greater supervision and control over our insurance subsidiaries' businesses and financial affairs. Our estimated consolidated statutory RBC ratio of our U.S. based insurance subsidiaries was 383 percent at December 31, 2024, compared to 402 percent at December 31, 2023.
During 2023, 2022 and 2021, we recognized an increase (decrease) in earnings of $(3.5) million, $48.9 million and $8.9 million, respectively, for the mark-to-market change in the agent deferred compensation plan liability which was impacted by changes in the underlying actuarial assumptions used to value the liability.
During 2024, 2023 and 2022, we recognized an increase (decrease) in earnings of $6.6 million, $(3.5) million and $48.9 million, respectively, for the mark-to-market change in the agent deferred compensation plan liability which was impacted by changes in the underlying actuarial assumptions used to value the liability.
Fluctuations by product line are discussed in greater detail in the narratives that follow. 60 Table of Contents Total allocated and unallocated expenses are summarized in the table below. Expenses not allocated to product lines include certain significant items listed in the table below.
Fluctuations by product line are discussed in greater detail in the narratives that follow.Total allocated and unallocated expenses are summarized in the table below. Expenses not allocated to product lines include certain significant items listed in the table below.
Such estimates are subject to numerous risks and uncertainties and the extent to which actual impacts differ from the assumptions used in our deferred tax valuation model. Based on our assessment, we have concluded that it is more likely than not that all our deferred tax assets of $937.1 million will be realized through future taxable earnings.
Such estimates are subject to numerous risks and uncertainties and the extent to which actual impacts differ from the assumptions used in our deferred tax valuation model. Based on our assessment, we have concluded that it is more likely than not that all our net deferred tax assets of $791.4 million will be realized through future taxable earnings.
Pursuant to the CLMA, CDOC will contribute funds to CNO Bermuda Re in the event: (i) CNO Bermuda Re's statutory economic capital and surplus is less than 150 percent of its ECR at the end of any calendar quarter; or (ii) CNO Bermuda Re's liquid assets are insufficient to meet its contractual obligations to ceding insurers, in each case, unless Bankers Life has provided notice of recapture pursuant to the terms of the Reinsurance Agreement.
Pursuant to the CLMA between CNO Bermuda Re and CDOC, CDOC will contribute funds to CNO Bermuda Re in the event: (i) CNO Bermuda Re's statutory economic capital and surplus is less than 150 percent of its ECR at the end of any calendar quarter; or (ii) CNO Bermuda Re's liquid assets are insufficient to meet its contractual obligations to ceding insurers, in each case, unless Bankers Life has provided notice of recapture pursuant to the terms of a modified coinsurance agreement between it and CNO Bermuda Re.
INVESTMENTS Our investment strategy is to: (i) provide largely stable investment income from a diversified high quality fixed income portfolio; (ii) mitigate the effect of changing interest rates through active asset/liability management; (iii) provide liquidity to meet our cash obligations to policyholders and others; (iv) maximize total return through active strategic asset allocation and investment management, while managing the capital efficiency of the portfolio; and (v) use outside managers in specialized investment classes to add value to our overall strategy.
INVESTMENTS Our investment strategy is to: (i) provide largely stable investment income from a diversified high quality fixed income portfolio; (ii) mitigate the effect of changing interest rates through active asset/liability management; (iii) provide liquidity to meet our cash obligations to policyholders and others; (iv) manage capital efficiency through active strategic asset allocation and investment management; and (v) use outside managers in specialized investment classes to add value to our overall strategy.
Free cash flow is a measure of holding company liquidity and is calculated as: (i) dividends, management fees and surplus debenture interest payments received from our subsidiaries; plus (ii) earnings on corporate investments; less (iii) interest expense, corporate expenses and net tax payments. In 2023, we generated $311 million of such free cash flow.
Free cash flow is a measure of holding company liquidity and is calculated as: (i) dividends, management fees and surplus debenture interest payments received from our subsidiaries; plus (ii) earnings on corporate investments; less (iii) interest expense, corporate expenses and net tax payments. In 2024, we generated $284.3 million of such free cash flow.
The 64 Table of Contents cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned.
The cash value rider is similar to the return of premium rider, but also provides for payment of a graded portion of the return of premium benefit if the policy terminates before the return of premium benefit is earned.
As the policies age, insurance policy benefits will typically increase, but the increase in benefits will be partially offset by investment income earned on the accumulated assets. Margin from Medicare supplement business was $116.9 million in 2023 compared to $151.0 million in 2022 and $162.5 million in 2021.
As the policies age, insurance policy benefits will typically increase, but the increase in benefits will be partially offset by investment income earned on the accumulated assets. Margin from Medicare supplement business was $113.9 million in 2024 compared to $116.9 million in 2023 and $151.0 million in 2022.
Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsurance business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.
Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account values for interest sensitive products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.
Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account balances for annuity products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsurance business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.
Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account values for interest sensitive products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.
We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change. During 2023, 2022 and 2021, we recognized an increase (decrease) in earnings of $(29.9) million, $440.2 million and $186.8 million, respectively, resulting from changes in the fair value of embedded derivative liabilities and MRBs related to our fixed indexed annuities.
We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change. During 2024, 2023 and 2022, we recognized an increase (decrease) in earnings of $24.7 million, $(29.9) million and $440.2 million, respectively, resulting from changes in the fair value of embedded derivative liabilities and MRBs related to our fixed indexed annuities.
The following table sets forth the aggregate amount of dividends (net of capital contributions) and other distributions that our insurance subsidiaries paid to our non-insurance subsidiaries in each of the last three fiscal years (dollars in millions): Years ended December 31, 2023 2022 2021 Dividends (net of contributions) from insurance subsidiaries $ 227.1 $ 129.0 $ 328.3 Surplus debenture interest 82.0 58.8 55.4 Fees for services provided pursuant to service agreements 116.1 124.0 117.8 Total dividends and other distributions paid by insurance subsidiaries $ 425.2 $ 311.8 $ 501.5 The ability of our U.S. based insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from GAAP.
The following table sets forth the aggregate amount of dividends (net of capital contributions) and other distributions that our insurance subsidiaries paid to our non-insurance subsidiaries in each of the last three fiscal years (dollars in millions): Years ended December 31, 2024 2023 2022 Dividends (net of contributions) from insurance subsidiaries $ 129.0 $ 227.1 $ 129.0 Surplus debenture interest 84.4 82.0 58.8 Fees for services provided pursuant to service agreements 119.7 116.1 124.0 Total dividends and other distributions paid by insurance subsidiaries $ 333.1 $ 425.2 $ 311.8 The ability of our U.S. based insurance subsidiaries to pay dividends is subject to state insurance department regulations and is based on the financial statements of our insurance subsidiaries prepared in accordance with statutory accounting practices prescribed or permitted by regulatory authorities, which differ from GAAP.
However, insurance regulators may prohibit payments by our insurance subsidiaries to parent companies if they determine that such payments could be adverse to our policyholders or contractholders.
However, insurance regulators may prohibit payments by our insurance subsidiaries to parent companies if they determine that such payments could be adverse to our policyholders or contract holders.
Over the last several years, we have experienced a shift in the sale of Medicare supplement policies to the sale of Medicare Advantage policies. We receive fee income when Medicare Advantage policies of other providers are sold, which is recorded in our Fee income segment.
In recent years, we have experienced a shift in the sale of Medicare supplement policies to the sale of Medicare Advantage policies. We receive fee income when Medicare Advantage policies of other providers are sold, which is recorded in our Fee income segment.
As of December 31, 2023, approximately 13 percent of our insurance liabilities had interest rates that may be reset annually; 48 percent had a fixed explicit interest rate for the duration of the contract; 36 percent are fixed indexed products where the income earned is subject to a participation rate that typically may be changed annually; and the remainder had no explicit interest rates.
As of December 31, 2024, approximately 13 percent of our insurance liabilities had interest rates that may be reset annually; 44 percent had a fixed explicit interest rate for the duration of the contract; 39 percent are fixed indexed products where the income earned is subject to a participation rate that typically may be changed annually; and the remainder had no explicit interest rates.
The amount and timing of future share repurchases (if any) will be based on business and market conditions and other factors including, but not limited to, available free cash flow, the current price of our common stock and investment opportunities. In 2023, we repurchased 6.6 million shares of common stock for $165.1 million under our securities repurchase program.
The amount and timing of future share repurchases (if any) will be based on business and market conditions and other factors including, but not limited to, available free cash flow, the current price of our common stock and investment opportunities. In 2024, we repurchased 8.9 million shares of common stock for $281.6 million under our securities repurchase program.
Net investment income and interest credited exclude the change in market values of the underlying options supporting the fixed indexed annuity products and corresponding offsetting amount credited to policyholder account balances. Such amounts were $118.3 million, $(181.3) million and $195.5 million in 2023, 2022 and 2021, respectively.
Net investment income and interest credited exclude the change in market values of the underlying options supporting the fixed indexed annuity products and corresponding offsetting amount credited to policyholder account balances. Such amounts were $231.8 million, $118.3 million and $(181.3) million in 2024, 2023 and 2022, respectively.
(d) These borrowings represent the securities issued by VIEs and include projected interest payments based on interest rates, as applicable, as of December 31, 2023. 78 Table of Contents (e) Includes benefits expected to be paid pursuant to our deferred compensation plan and postretirement plans based on numerous actuarial assumptions and interest credited at 5.00 percent.
(d) These borrowings represent the securities issued by VIEs and include projected interest payments based on interest rates, as applicable, as of December 31, 2024. (e) Includes benefits expected to be paid pursuant to our deferred compensation plan and postretirement plans based on numerous actuarial assumptions and interest credited at 5.50 percent.
The following tables summarize the impacts of our comprehensive annual actuarial reviews in 2023, 2022 and 2021 (dollars in millions): Insurance policy Line of business benefits 2023 Fixed indexed annuities $ 9.4 Other annuities 3.5 Supplemental health 41.9 Medicare supplement (10.6) Long-term care (9.0) Traditional life (5.2) Interest-sensitive life 3.9 Favorable impact on pre-tax operating income $ 33.9 2022 Fixed indexed annuities $ (3.2) Supplemental health 1.9 Long-term care 16.4 Traditional life (13.0) Interest-sensitive life (1.4) Favorable impact on pre-tax operating income $ .7 2021 Fixed indexed annuities $ (.7) Supplemental health 1.5 Medicare supplement 6.0 Long-term care (.4) Traditional life (2.5) Interest-sensitive life (.9) Favorable impact on pre-tax operating income $ 3.0 Summary of Operating Results: Net operating income was $356.1 million in 2023, compared to $360.4 million in 2022 and $400.4 million in 2021.
The following tables summarize the impacts of our comprehensive annual actuarial reviews on our operating income for the years ended December 31, 2024, 2023 and 2022 (dollars in millions): Insurance policy benefits Line of business 2024 2023 2022 Fixed indexed annuities $ 36.2 $ 9.4 $ (3.2) Other annuities — 3.5 — Supplemental health 0.3 41.9 1.9 Medicare supplement (9.4) (10.6) — Long-term care 0.9 (9.0) 16.4 Traditional life (4.5) (5.2) (13.0) Interest-sensitive life 3.8 3.9 (1.4) Favorable impact on pre-tax operating income $ 27.3 $ 33.9 $ 0.7 Summary of Operating Results: Net operating income was $429.3 million in 2024, compared to $356.1 million in 2023 and $360.4 million in 2022.
The return of premium rider generally provides that after a policy has been inforce for a specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy.
The return of premium rider generally provides that after a policy has been inforce for a 69 Table of Co n t e n t s specified number of years or upon the policyholder reaching a specified age, we will pay to the policyholder, or a beneficiary under the policy, the aggregate amount of all premiums paid under the policy, without interest, less the aggregate amount of all claims incurred under the policy.
General account investments exclude the value of options. 2023 2022 2021 (dollars in millions) Weighted average investments at amortized cost allocated to product lines $ 20,567.5 $ 19,987.5 $ 19,098.8 Allocated investment income 957.8 915.2 905.6 Average yield on allocated investments 4.66 % 4.58 % 4.74 % Insurance statutes regulate the types of investments that our insurance subsidiaries are permitted to make and limit the amount of funds that may be used for any one type of investment.
General account investments exclude the value of options. 2024 2023 2022 (dollars in millions) Weighted average investments at amortized cost allocated to product lines $ 21,085.8 $ 20,567.5 $ 19,987.5 Allocated investment income 1,011.8 957.8 915.2 Average yield on allocated investments 4.80 % 4.66 % 4.58 % Insurance statutes regulate the types of investments that our insurance subsidiaries are permitted to make and limit the amount of funds that may be used for any one type of investment.
We estimate that our fixed maturity securities and short-term investments would decline in fair value by approximately $650 million if interest rates were to increase by 10 percent from their levels at December 31, 2023.
We estimate that our fixed maturity securities and short-term investments would decline in fair value by $729.6 million if interest rates were to increase by 10 percent from their levels at December 31, 2024.
Such non-deferred commissions are included in other operating costs and expenses on the consolidated statement of operations. 58 Table of Contents General: CNO is the top tier holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products.
Such non-deferred commissions are included in other operating costs and expenses on the consolidated statement of operations. 63 Table of Co n t e n t s General: CNO is the top tier holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products.
Such earnings are not indicative of, and are unrelated to, the Company's underlying fundamentals. 68 Table of Contents PREMIUM COLLECTIONS In accordance with GAAP, insurance policy income in our consolidated statement of operations consists of premiums earned for traditional insurance policies that have life contingencies or morbidity features.
Such earnings are not indicative of, and are unrelated to, the Company's underlying fundamentals. 73 Table of Co n t e n t s PREMIUM COLLECTIONS In accordance with GAAP, insurance policy income in our consolidated statement of operations consists of premiums earned for traditional insurance policies that have life contingencies or morbidity features.
Refer to "- Liquidity for Insurance Operations" above regarding the CLMA and limitations on CNO Bermuda Re's ability to pay dividends or other capital distributions to CDOC. 81 Table of Contents At December 31, 2023, CNO, CDOC and our other non-insurance subsidiaries held $255.6 million of unrestricted cash and cash equivalents which was above our minimum target level of $150 million.
Refer to "- Liquidity for Insurance Operations" above regarding the CLMA and limitations on CNO Bermuda Re's ability to pay dividends or other capital distributions to CDOC. At December 31, 2024, CNO, CDOC and our other non-insurance subsidiaries held $372.5 million of unrestricted cash and cash equivalents which was above our minimum target level of $150 million.
At December 31, 2023, we held investments with an amortized cost of $787.6 million and an estimated fair value of $768.6 million related to VIEs that we are required to consolidate. The investment portfolio held by the VIEs is primarily comprised of commercial bank loans, the borrowers for which are almost entirely rated below-investment grade.
At December 31, 2024, we held investments with an amortized cost of $437.0 million and an estimated fair value of $432.3 million related to VIEs that we are required to consolidate. The investment portfolio held by the VIEs is primarily comprised of commercial bank loans, the borrowers for which are almost entirely rated below-investment grade.
The increase in net insurance liabilities results in higher net investment income allocated. The earned yield was 4.39 percent in 2023, up from 4.25 percent in 2022, reflecting higher portfolio yields, and down slightly from 4.42 percent in 2021.
The increase in net insurance liabilities results in higher net investment income allocated. The earned yield was 4.66 percent in 2024, up from 4.39 percent in 2023 and 4.25 percent in 2022, reflecting higher portfolio yields.
The weighted average crediting rates at December 31, 2023, related to such annuity and universal life account values, that were at the minimum guaranteed crediting rate were 2.21 percent and 4.0 percent, respectively.
The weighted average crediting rates at December 31, 2024, related to such annuity and universal life account values, that were at the minimum guaranteed crediting rate were 2.66 percent and 4.17 percent, respectively.
We expect our expense ratio to be in the range of 18.8 percent to 19.2 percent, with a quarterly trend similar to 2023, starting on the high end in the first quarter of the year and then grading down throughout the year.
We expect our expense ratio to be in the range of 19.0 percent to 19.4 percent, with a quarterly trend similar to 2024, starting on the high end in the first quarter of the year and then grading down throughout the year.
We carry trading securities at estimated fair value; changes in fair value are reflected in the statement of operations. Our trading securities include: (i) investments purchased with the intent of selling in the near term to generate income; and (ii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option.
Our trading securities include: (i) investments purchased with the intent of selling in the near term to generate income; and (ii) certain fixed maturity securities containing embedded derivatives for which we have elected the fair value option.
Investment Income Not Allocated to Product Lines (dollars in millions): 2023 2022 2021 Net investment income $ 1,499.7 $ 1,015.9 $ 1,420.7 Allocated to product lines: Annuity (516.3) (480.0) (468.9) Health (296.7) (293.3) (293.5) Life (144.8) (141.9) (143.2) Equity returns credited to policyholder account balances (131.5) 205.3 (219.8) Amounts allocated to product lines and credited to policyholder account balances (1,089.3) (709.9) (1,125.4) Impact of annual option forfeitures related to fixed indexed annuity surrenders 7.1 (1.0) 15.2 Amount related to variable interest entities and other non-operating items (74.8) (48.5) (30.5) Interest expense on debt (62.7) (62.5) (62.4) Interest expense on financing arrangements (2.4) — — Interest expense on investment borrowings from FHLB (104.7) (33.5) (9.8) Expenses related to FABN program (30.4) (30.0) (2.3) Less amounts credited to deferred compensation plans (offsetting investment income) (22.3) 13.4 (16.6) Total adjustments (290.2) (162.1) (106.4) Investment income not allocated to product lines $ 120.2 $ 143.9 $ 188.9 The above table reconciles net investment income to investment income not allocated to product lines.
Investment Income Not Allocated to Product Lines (dollars in millions): 2024 2023 2022 Net investment income $ 1,748.8 $ 1,499.7 $ 1,015.9 Allocated to product lines: Annuity (565.0) (516.3) (480.0) Health (299.6) (296.7) (293.3) Life (147.1) (144.8) (141.9) Equity returns credited to policyholder account balances (253.7) (131.5) 205.3 Amounts allocated to product lines and credited to policyholder account balances (1,265.4) (1,089.3) (709.9) Impact of annual option forfeitures related to fixed indexed annuity surrenders 26.0 7.1 (1.0) Amount related to variable interest entities and other non-operating items (33.5) (74.8) (48.5) Interest expense on debt (91.8) (62.7) (62.5) Interest expense on financing arrangements (4.7) (2.4) — Interest expense on investment borrowings from FHLB (123.2) (104.7) (33.5) Expenses related to FABN program (64.0) (30.4) (30.0) Less amounts credited to deferred compensation plans (offsetting investment income) (24.3) (22.3) 13.4 Total adjustments (315.5) (290.2) (162.1) Investment income not allocated to product lines $ 167.9 $ 120.2 $ 143.9 The above table reconciles net investment income to investment income not allocated to product lines.
Our commercial mortgage loan portfolio is primarily comprised of large commercial mortgage loans. Approximately 16 percent, 8 percent, 6 percent and 6 percent of the commercial mortgage loan balance were on properties located in California, Maryland, Wisconsin and Indiana, respectively. No other state comprised greater than five percent of the mortgage loan balance.
Our commercial mortgage loan portfolio is primarily comprised of large commercial mortgage loans. Approximately 17 percent, 7 percent, 6 percent, 6 percent, and 5 percent of the commercial mortgage loan balance were on properties located in California, Maryland, Wisconsin, Utah and Georgia, respectively. No other state comprised greater than five percent of the mortgage loan balance.
Total asset adequacy and premium deficiency reserves for Bankers Life, Washington National and Bankers Conseco Life Insurance Company were $70.0 million, $134.5 million and $34.5 million, respectively, at December 31, 2023.
Total asset adequacy and premium deficiency reserves for Bankers Life, Washington National and Bankers Conseco Life Insurance Company were $90.0 million, $51.0 million and $34.5 million, respectively, at December 31, 2024.
In addition, the impact of actual adjustments would reflect the net effect of all changes in assumptions during the period. 55 Table of Contents Change in assumptions Estimated adjustment to income before income taxes based on revisions to certain assumptions (dollars in millions) Annuities Fixed indexed and fixed interest annuity products: 5% increase to assumed mortality $ 3 5% decrease to assumed mortality (4) 10% increase to assumed surrender rate (3) 10% decrease to assumed surrender rate 2 50 basis point increase in interest rates (a) 68 50 basis point decrease in interest rates (a) (75) Other annuities: 5% increase to assumed mortality 5 5% decrease to assumed mortality (5) Health Medicare supplement: 5% increase to assumed mortality 2 5% decrease to assumed mortality (2) 10% increase to assumed lapse rate 3 10% decrease to assumed lapse rate (3) 10% increase to assumed morbidity (49) 10% decrease to assumed morbidity 48 Supplemental health: 5% increase to assumed mortality 8 5% decrease to assumed mortality (9) 10% increase to assumed lapse rate 20 10% decrease to assumed lapse rate (20) 10% increase to assumed morbidity (21) 10% decrease to assumed morbidity 21 Long-term care: 5% increase to assumed mortality 32 5% decrease to assumed mortality (34) 10% increase to assumed lapse rate 20 10% decrease to assumed lapse rate (20) 10% increase to assumed morbidity (75) 10% decrease to assumed morbidity 68 Life Traditional life: 5% increase to assumed mortality (34) 5% decrease to assumed mortality 35 10% increase to assumed lapse rate 6 10% decrease to assumed lapse rate (6) Interest-sensitive life products: 5% increase to assumed mortality (6) 5% decrease to assumed mortality 6 10% increase to assumed lapse rate 1 10% decrease to assumed lapse rate (1) _____________________ (a) The estimated impact of the hypothetical 50 basis point increase or decrease in interest rates related to our fixed indexed and fixed interest annuity products would be reflected in our pre-tax non-operating earnings. 56 Table of Contents The following summarizes the persistency of our major blocks of insurance business summarized by line of business: Years ended December 31, 2023 2022 2021 Annuity: Fixed indexed annuities (1) 89.7 % 90.9 % 90.9 % Fixed interest annuities (1) 83.4 % 83.9 % 84.8 % Other annuities (2) 97.2 % 95.7 % 96.8 % Health: Supplemental health (3) 88.5 % 88.2 % 88.8 % Medicare supplement (3) 84.3 % 82.1 % 82.6 % Long-term care (3) 90.5 % 91.0 % 87.7 % Life: Traditional life (3) 83.9 % 84.0 % 84.8 % Interest-sensitive life (3) 89.1 % 88.8 % 88.7 % _____________________ (1) Based on the total amount of death benefits, surrenders values and partial withdrawals divided by the average account value.
In addition, the impact of actual adjustments would reflect the net effect of all changes in assumptions during the period. 59 Table of Co n t e n t s Change in assumptions Estimated adjustment to income before income taxes based on revisions to certain assumptions (dollars in millions) Annuities Fixed indexed and fixed interest annuity products: 5% increase to assumed mortality $ 2 5% decrease to assumed mortality (2) 10% increase to assumed lapse rate (4) 10% decrease to assumed lapse rate 4 50 basis point increase in interest rates (a) 74 50 basis point decrease in interest rates (a) (80) Other annuities: 5% increase to assumed mortality 5 5% decrease to assumed mortality (5) Health Medicare supplement: 5% increase to assumed mortality 2 5% decrease to assumed mortality (2) 10% increase to assumed lapse rate 3 10% decrease to assumed lapse rate (3) 10% increase to assumed morbidity (57) 10% decrease to assumed morbidity 57 Supplemental health: 5% increase to assumed mortality 10 5% decrease to assumed mortality (11) 10% increase to assumed lapse rate 24 10% decrease to assumed lapse rate (24) 10% increase to assumed morbidity (25) 10% decrease to assumed morbidity 25 Long-term care: 5% increase to assumed mortality 34 5% decrease to assumed mortality (37) 10% increase to assumed lapse rate 21 10% decrease to assumed lapse rate (22) 10% increase to assumed morbidity (81) 10% decrease to assumed morbidity 75 Life Traditional life: 5% increase to assumed mortality (42) 5% decrease to assumed mortality 43 10% increase to assumed lapse rate 6 10% decrease to assumed lapse rate (7) Interest-sensitive life products: 5% increase to assumed mortality (5) 5% decrease to assumed mortality 6 10% increase to assumed lapse rate 1 10% decrease to assumed lapse rate (1) _____________________ (a) The estimated impact of the hypothetical 50 basis point increase or decrease in interest rates related to our fixed indexed and fixed interest annuity products would be reflected in our pre-tax non-operating earnings. 60 Table of Co n t e n t s The following summarizes the persistency of our major blocks of insurance business summarized by line of business: Years ended December 31, 2024 2023 2022 Annuity: Fixed indexed annuities (1) 88.1 % 89.7 % 90.9 % Fixed interest annuities (1) 82.9 % 83.4 % 83.9 % Other annuities (2) 90.6 % 97.2 % 95.7 % Health: Medicare supplement (3) 84.1 % 84.3 % 82.1 % Supplemental health (3) 88.0 % 88.5 % 88.2 % Long-term care (3) 91.1 % 90.5 % 91.0 % Life: Traditional life (3) 84.1 % 83.9 % 84.0 % Interest-sensitive life (3) 88.7 % 89.1 % 88.8 % _____________________ (1) Based on the total amount of death benefits, surrender values and partial withdrawals divided by the average account value.
We expect a significant improvement in net investment income not allocated to product lines, which assumes higher returns on our alternative investments.
We expect improved results in net investment income not allocated to product lines, which assumes higher returns on our alternative investments.
On November 15, 2023, Fitch upgraded the financial strength ratings of our primary insurance subsidiaries to "A" from "A-" and the outlook for these ratings is stable. An insurer rated "A", in Fitch's opinion, indicates a low expectation of ceased or interrupted payments and indicates strong capacity to meet policyholder and contract obligations.
On October 29, 2024, Fitch affirmed its "A" financial strength ratings of our primary insurance subsidiaries and the outlook for these ratings is stable. An insurer rated "A", in Fitch's opinion, indicates a low expectation of ceased or interrupted payments and indicates strong capacity to meet policyholder and contract obligations.
Further, CNO Bermuda Re may not pay any dividends or make any capital distributions to its parent and/or affiliates within the five years following the initial reinsurance transaction unless approved by the BMA.
Further, CNO Bermuda Re may not pay any dividends 85 Table of Co n t e n t s or make any capital distributions to its parent and/or affiliates within the five years following the initial reinsurance transaction unless approved by the BMA.
At December 31, 2023, the estimated duration of our fixed income securities (as modified to reflect estimated prepayments and call premiums) and the estimated duration of our insurance liabilities were approximately 8.1 years and 8.2 years, respectively.
At December 31, 2024, the estimated duration of our fixed income securities (as modified to reflect estimated prepayments and call premiums) and the estimated duration of our insurance liabilities were approximately 7.9 years and 8.4 years, respectively.
In estimating the payments we expect to make to our policyholders, we considered the following: • For products such as immediate annuities and structured settlement annuities without life contingencies, the payment obligation is fixed and determinable based on the terms of the policy. • For products such as universal life, ordinary life, long-term care, supplemental health and deferred annuities, the future payments are not due until the occurrence of an insurable event (such as death or disability) or a triggering event (such as a surrender or partial withdrawal).
As such payments are based on numerous assumptions, the actual payments may vary significantly from the amounts shown. 83 Table of Co n t e n t s In estimating the payments we expect to make to our policyholders, we considered the following: • For products such as immediate annuities and structured settlement annuities without life contingencies, the payment obligation is fixed and determinable based on the terms of the policy. • For products such as universal life, ordinary life, long-term care, supplemental health and deferred annuities, the future payments are not due until the occurrence of an insurable event (such as death or disability) or a triggering event (such as a surrender or partial withdrawal).
At December 31, 2023, the weighted average yield, computed on the cost basis of investments allocated to our product lines, was approximately 4.7 percent, and the average interest rate credited or accruing to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable to variable or 84 Table of Contents fixed indexed products) was 4.4 percent.
At December 31, 2024, the weighted average yield, computed on the cost basis of investments allocated to our product lines, was approximately 4.8 percent, and the average interest rate credited or accruing to our total insurance liabilities (excluding interest rate bonuses for the first policy year only and excluding the effect of credited rates attributable 90 Table of Co n t e n t s to variable or fixed indexed products) was 4.3 percent.
We expect to receive regulatory approval for future dividends from our subsidiaries, but there can be no assurance that such payments will be approved or that the financial condition of our insurance subsidiaries will not change, making future approvals less likely.
We expect to receive regulatory approval for future dividends from our subsidiaries, but there can be no assurance that such payments will be approved or that the financial condition of our insurance subsidiaries will not change, making future approvals less likely. During 2024, CDOC made capital contributions of $67.0 million to its insurance subsidiaries.
During 2023, 2022 and 2021, we recognized a decrease in earnings of $6.3 million, $73.2 million and $17.4 million, respectively, due to the net change in market value of investments recognized in earnings. The change in value will fluctuate from period to period based on market conditions.
During 2024, 2023 and 2022, we recognized an increase (decrease) in earnings of $22.8 million, $(6.3) million and $(73.2) million, respectively, due to the net change in market value of investments recognized in earnings. The change in value will fluctuate from period to period based on market conditions.
Consistent with this strategy, investments in fixed maturity securities and mortgage loans made up 90 percent of our $26.1 billion investment portfolio at December 31, 2023. The remainder of the invested assets was trading securities, investments held by VIEs, equity securities, policy loans and other invested assets.
Consistent with this strategy, investments in fixed maturity securities and mortgage loans made up 91 percent of our $27.9 billion investment portfolio at December 31, 2024. The remainder of the invested assets were trading securities, investments held by VIEs, equity securities, policy loans and other invested assets.
There are six ratings above the "A-" rating of our primary insurance subsidiaries and fourteen ratings that are below that rating. Moody's most recently reviewed its "A3" financial strength ratings of our primary insurance subsidiaries on May 12, 2023. The outlook for these ratings remains stable. Moody’s financial strength ratings range from "Aaa" to "C".
There are five ratings above the "A" rating of our primary insurance subsidiaries and thirteen ratings that are below that rating. Moody's most recently reviewed its "A3" financial strength ratings of our primary insurance subsidiaries on July 10, 2024. The outlook for these ratings remains stable. Moody’s financial strength ratings range from "Aaa" to "C".
There are five ratings above the "A" rating of our primary insurance subsidiaries and thirteen ratings that are below that rating. S&P most recently reviewed its "A-" financial strength ratings of our primary insurance subsidiaries on June 23, 2023. The outlook for these ratings is stable.
There are six ratings above the "A3" rating of our primary insurance subsidiaries and fourteen ratings that are below that rating. S&P most recently reviewed its "A-" financial strength ratings of our primary insurance subsidiaries on June 4, 2024. The outlook for these ratings is stable.
Any future increase in the valuation allowance may result in additional income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future.
The recognition of a valuation allowance would increase income tax expense and reduce shareholders' equity, and such an increase could have a significant impact upon our earnings in the future.
The interest-sensitive life margins excluding the impacts of the actuarial review changes previously discussed were $94.8 million, $80.9 million and $67.2 million in 2023, 2022 and 2021, respectively. The increase in margin in 2023 and 2022 reflects more favorable mortality and growth in the block due to sales in recent periods.
The interest-sensitive life margins adjusted to exclude the impacts of the annual actuarial review previously discussed were $94.1 million, $94.8 million and $80.9 million in 2024, 2023 and 2022, respectively. The increase in the adjusted margin in 2024 and 2023 compared to 2022 reflects more favorable mortality and growth in the block due to sales in recent periods.
Changes to our cash flow assumptions are recognized in the liability for future policy benefits remeasurement (gain) loss in the consolidated statement of operations.
A more detailed review of assumptions is performed annually. Changes to our cash flow assumptions are recognized in the liability for future policy benefits remeasurement (gain) loss in the consolidated statement of operations.
Our investment strategy is to maximize, over a sustained period and within acceptable parameters of quality and risk, investment income and total investment return through active strategic asset allocation and investment management.
Our investment strategy is to manage, over a sustained period and within acceptable parameters of quality and risk, capital efficiency through active strategic asset allocation and investment management.
Insurance product margin was $959.0 million, $936.5 million and $953.4 million in 2023, 2022 and 2021, respectively. Insurance product margin, excluding the impacts summarized in the table above, were $925.1 million, $935.8 million and $950.4 million in 2023, 2022 and 2021, respectively.
Insurance product margin was $1,040.0 million, $959.0 million and $936.5 million in 2024, 2023 and 2022, respectively. Insurance product margin, excluding the impacts summarized in the table above, were $1,012.7 million, $925.1 million and $935.8 million in 2024, 2023 and 2022, respectively.
Such changes are recognized in the current period as a reduction of the capitalized balances. The effect of changes in assumptions related to future mortality and lapses are recognized prospectively over the remaining contract term.
Such changes are recognized in the current period as a reduction of the capitalized balances. The effect of changes in assumptions related to future mortality and lapses are recognized prospectively over the remaining contract term. The carrying values of deferred acquisition costs are not subject to recovery testing.
Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information on these investments. LIQUIDITY AND CAPITAL RESOURCES 2024 Outlook We expect operating earnings per diluted share to be in the range of $3.10 to $3.30, excluding any significant items in the year.
Refer to the note to the consolidated financial statements entitled "Investments in Variable Interest Entities" for additional information on these investments. 81 Table of Co n t e n t s LIQUIDITY AND CAPITAL RESOURCES 2025 Outlook We expect operating earnings per diluted share to be in the range of $3.70 to $3.90, excluding any significant items in the year.
However, as each of the immediate U.S. based insurance subsidiaries of CDOC has significant negative earned surplus, any dividend payments from the insurance subsidiaries require the prior approval of the director or commissioner of the applicable state insurance department. In 2023, our U.S. based insurance subsidiaries paid dividends to CDOC totaling $526.5 million.
However, as each of the immediate U.S. based insurance subsidiaries of CDOC has significant negative earned surplus, any dividend payments from the insurance subsidiaries require the prior approval of the director or commissioner of the applicable state insurance department.
Outlook We believe that the existing cash available to the holding company, the cash flows to be generated from operations and other transactions will be sufficient to allow us to meet our debt service obligations, pay corporate expenses and satisfy other financial obligations.
There are nine ratings above CNO's "Baa3" rating and eleven ratings that are below its rating. Outlook We believe that the existing cash available to the holding company, the cash flows to be generated from operations and other transactions will be sufficient to allow us to meet our debt service obligations, pay corporate expenses and satisfy other financial obligations.
We receive fee income when Medicare Advantage policies of other providers are sold, which is recorded in our Fee income segment. We continue to invest in both our Medicare supplement products and Medicare Advantage distribution to ensure we are well-positioned to meet our customers' needs and preferences. For example, we launched a new competitive Medicare supplement product in 2022.
We receive fee income when Medicare Advantage policies of other providers are sold, which is recorded in our Fee income segment. We continue to invest in both our Medicare supplement products and Medicare Advantage distribution to meet our customers' needs and preferences.
Such amount will generally fluctuate from period to period based on the level of prepayment income (including call premiums) and trading account income; the performance of our alternative investments (which are typically reported a quarter in arrears); the earnings related to the investments underlying our COLI; and the spread we earn from our FHLB investment borrowing and FABN programs. 67 Table of Contents Net Non-Operating Income (Loss): The following summarizes our net non-operating income (loss) for the three years ended December 31, 2023 (dollars in millions): 2023 2022 2021 Net realized investment gains (losses) from sales, impairments and change in allowance for credit losses $ (62.7) $ (62.2) $ 36.5 Net change in market value of investments recognized in earnings (6.3) (73.2) (17.4) Fair value changes related to agent deferred compensation plan (3.5) 48.9 8.9 Changes in fair value of embedded derivative liabilities and market risk benefits (29.9) 440.2 186.8 Other (.3) (3.9) 3.6 Net non-operating income (loss) before taxes $ (102.7) $ 349.8 $ 218.4 Net realized investment losses were $62.7 million in 2023, including the favorable change in the allowance for credit losses of $8.1 million which were recorded in earnings.
Other factors driving fluctuations include the performance of our alternative investments (which are typically reported a quarter in arrears); the earnings related to the investments underlying our COLI; the spread we earn from our FHLB investment borrowing and FABN programs; and the level of prepayment income (including call premiums) and trading account income. 72 Table of Co n t e n t s Net Non-Operating Income (Loss): The following summarizes our net non-operating income (loss) for each of the three years ended December 31, 2024 (dollars in millions): 2024 2023 2022 Net realized investment gains (losses) from sales, impairments and change in allowance for credit losses $ (72.7) $ (62.7) $ (62.2) Net change in market value of investments recognized in earnings 22.8 (6.3) (73.2) Fair value changes related to agent deferred compensation plan 6.6 (3.5) 48.9 Changes in fair value of embedded derivative liabilities and market risk benefits 24.7 (29.9) 440.2 Other (13.9) (0.3) (3.9) Net non-operating income (loss) before taxes $ (32.5) $ (102.7) $ 349.8 Net realized investment losses were $72.7 million in 2024, net of reductions in the allowance for credit losses of $9.4 million which were recorded in earnings.
The following summarizes our earnings for the three years ended December 31, 2023 (dollars in millions, except per share data): 2023 2022 2021 Insurance product margin Annuity margin $ 235.0 $ 226.9 $ 243.2 Health margin 494.3 504.4 497.6 Life margin 229.7 205.2 212.6 Total insurance product margin 959.0 936.5 953.4 Allocated expenses (599.0) (596.6) (566.5) Income from insurance products 360.0 339.9 386.9 Fee income 31.0 23.7 19.4 Investment income not allocated to product lines 120.2 143.9 188.9 Expenses not allocated to product lines (51.7) (40.8) (80.5) Operating earnings before taxes 459.5 466.7 514.7 Income tax expense on operating income (103.4) (106.3) (114.3) Net operating income (a) 356.1 360.4 400.4 Net realized investment gains (losses) from sales, impairments and change in allowance for credit losses (62.7) (62.2) 36.5 Net change in market value of investments recognized in earnings (6.3) (73.2) (17.4) Fair value changes related to agent deferred compensation plan (3.5) 48.9 8.9 Changes in fair value of embedded derivative liabilities and market risk benefits (29.9) 440.2 186.8 Other (.3) (3.9) 3.6 Net non-operating income (loss) before taxes (102.7) 349.8 218.4 Income tax expense (benefit) on non-operating income (loss) (23.1) 79.6 48.5 Net non-operating income (loss) (79.6) 270.2 169.9 Net income $ 276.5 $ 630.6 $ 570.3 Per diluted share: Net operating income $ 3.09 $ 3.06 $ 3.05 Net non-operating income (loss) (.69) 2.30 1.30 Net income $ 2.40 $ 5.36 $ 4.35 50 Table of Contents ____________ (a) Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits ("MRBs") related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) loss related to reinsurance transactions, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items consisting primarily of earnings attributable to VIEs, net of taxes ("net operating income", a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry.
Expenses not allocated to product lines primarily include the expenses of our corporate operations, excluding interest expense on debt. 54 Table of Co n t e n t s The following summarizes our earnings for each of the three years ended December 31, 2024 (dollars in millions, except per share data): 2024 2023 2022 Insurance product margin Annuity margin $ 274.2 $ 235.0 $ 226.9 Health margin 516.8 494.3 504.4 Life margin 249.0 229.7 205.2 Total insurance product margin 1,040.0 959.0 936.5 Allocated expenses (615.3) (599.0) (596.6) Income from insurance products 424.7 360.0 339.9 Fee income 30.0 31.0 23.7 Investment income not allocated to product lines 167.9 120.2 143.9 Expenses not allocated to product lines (71.8) (51.7) (40.8) Operating earnings before taxes 550.8 459.5 466.7 Income tax expense on operating income (121.5) (103.4) (106.3) Net operating income (a) 429.3 356.1 360.4 Net realized investment losses from sales, impairments and change in allowance for credit losses (72.7) (62.7) (62.2) Net change in market value of investments recognized in earnings 22.8 (6.3) (73.2) Fair value changes related to agent deferred compensation plan 6.6 (3.5) 48.9 Changes in fair value of embedded derivative liabilities and market risk benefits 24.7 (29.9) 440.2 Other (13.9) (0.3) (3.9) Net non-operating income (loss) before taxes (32.5) (102.7) 349.8 Income tax expense (benefit) on non-operating income (loss) (7.2) (23.1) 79.6 Net non-operating income (loss) (25.3) (79.6) 270.2 Net income $ 404.0 $ 276.5 $ 630.6 Per diluted share: Net operating income $ 3.97 $ 3.09 $ 3.06 Net non-operating income (loss) (0.23) (0.69) 2.30 Net income $ 3.74 $ 2.40 $ 5.36 __________ (a) Management believes that an analysis of net income applicable to common stock before: (i) net realized investment gains or losses from sales, impairments and the change in allowance for credit losses, net of taxes; (ii) net change in market value of investments recognized in earnings, net of taxes; (iii) changes in fair value of embedded derivative liabilities and market risk benefits ("MRBs") related to our fixed indexed annuities, net of taxes; (iv) fair value changes related to the agent deferred compensation plan, net of taxes; (v) gains or losses related to material reinsurance transactions, net of taxes; (vi) loss on extinguishment of debt, net of taxes; (vii) changes in the valuation allowance for deferred tax assets and other tax items; and (viii) other non-operating items including earnings attributable to variable interest entities, net of taxes ("net operating income," a non-GAAP financial measure) is important to evaluate the financial performance of the company, and is a key measure commonly used in the life insurance industry.
Margin from Long-term care products was $83.0 million in 2023 compared to $122.5 million in 2022 and $118.2 million in 2021. The margin excluding the impacts of the actuarial review changes previously discussed was $92.0 million, $106.1 million and $118.6 million in 2023, 2022 and 2021, respectively.
Margin from Long-term care products was $133.1 million in 2024 compared to $83.0 million in 2023 and $122.5 million in 2022. The margin adjusted to exclude the impacts of the annual actuarial review previously discussed was $132.2 million, $92.0 million and $106.1 million in 2024, 2023 and 2022, respectively.
For example, the following events could have a material adverse effect on our cash flows: • An adverse decision in pending or future litigation. • An inability to obtain rate increases on certain of our insurance products. • Worse than anticipated claims experience. • Lower than expected dividends and/or surplus debenture interest payments from our insurance subsidiaries (resulting from inadequate earnings or capital or regulatory requirements). • An inability to meet and/or maintain the covenants in our Revolving Credit Agreement. • A significant increase in policy surrender levels. • A significant increase in investment defaults. • An inability of our reinsurers to meet their financial obligations.
For example, the following events could have a material adverse effect on our cash flows: • An adverse decision in pending or future litigation. • An inability to obtain rate increases on certain of our insurance products. • Worse than anticipated claims experience. • Lower than expected dividends and/or surplus debenture interest payments from our insurance subsidiaries (resulting from inadequate earnings or capital or regulatory requirements). • An inability to meet and/or maintain the covenants in our Revolving Credit Agreement. • A significant increase in policy surrender levels. • A significant increase in investment defaults. • An inability of our reinsurers to meet their financial obligations. 84 Table of Co n t e n t s While we actively manage the relationship between the duration and cash flows of our invested assets and the estimated duration and cash flows of benefit payments arising from contract liabilities, there could be significant variations in the timing of such cash flows.